ReviewAmerican journal of translational research2026
Antioxidant and immunomodulatory activities of sericin and its applications in tumor prevention and treatment.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sericin, a by-product of silk processing, shows great potential in tumor prevention and treatment owing to its excellent antioxidant and immunomodulatory properties. Its structure, which is rich in polar amino acids, endows sericin with high hydrophilicity and biocompatibility, allowing it to suppress cancer cell proliferation and induce apoptosis by scavenging reactive oxygen species and modulating the PI3K/Akt pathway and autophagy-related pathways. In the complex tumor microenvironment, sericin acts as an effective immune modulator. Instead of inducing widespread immunosuppression, it modulates the immune microenvironment by attenuating pro-tumorigenic chronic inflammation and potentially preserving or indirectly enhancing the cytolytic activity of natural killer cells. By balancing macrophage responses and alleviating oxidative stress-induced immune exhaustion, sericin helps restore immune surveillance. The antitumor effect of sericin is not achieved through nonspecific immune activation, but rather by restoring redox homeostasis and reshaping the inflammatory environment, thereby transforming the tumor microenvironment from a pro-cancer state to one conducive to immune surveillance. As a natural antioxidant and drug delivery carrier, sericin shows potential for targeted delivery and low toxicity in combined chemoradiotherapy and nanotechnology-enabled diagnostic and therapeutic systems. However, issues related to stability and production scalability still need to be addressed before its widespread clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.